Study design and endpoints in graft-versus-host disease
1Division of Clinical Research, Fred Hutchinson Cancer Research Center, P.O. Box 19024, 1100 Fairview Avenue North, Suite D2-100, Seattle, WA 98109-1024, USA. pmartin@fhcrc.org
Best Practice & Research. Clinical Haematology
|May 28, 2008
Summary
Designing clinical trials for graft-versus-host disease (GVHD) requires careful endpoint selection and outcome assessment. Addressing challenges like patient enrollment and concomitant treatments is crucial for successful trial completion.
Area of Science:
- Hematology
- Immunology
- Clinical Trial Design
Background:
- Graft-versus-host disease (GVHD) presents significant challenges in clinical trial design.
- Effective prevention and treatment strategies require robust trial methodologies.
Purpose of the Study:
- To outline key considerations for designing effective clinical trials for acute and chronic GVHD.
- To identify critical elements for demonstrating clinical benefit and assessing treatment success.
Main Methods:
- Review of challenges in endpoint selection for GVHD trials.
- Analysis of response assessment criteria, including prior trajectory and concomitant treatments.
- Emphasis on pre-specification of hypotheses and consideration of enrollment barriers.
Main Results:
- Clinical trials for GVHD necessitate specific primary and secondary endpoints to show benefit.
- Response assessment must account for patient history, concurrent therapies, and other complications.
- Quantitative hypothesis pre-specification and proactive enrollment barrier management are vital.
Conclusions:
- Successful GVHD clinical trials depend on meticulous planning of endpoints and outcome measures.
- Comprehensive assessment strategies are needed to accurately evaluate treatment efficacy.
- Addressing logistical and methodological hurdles ensures trial integrity and timely completion.
